EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC

NCT07647289 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

58

Enrollment

OTHER

Sponsor class

Conditions

Muscle-Invasive Bladder Cancer (MIBC)

Interventions

DRUG: enfortumab vedotin (EV)
DRUG: Toripalimab
DRUG: Gemcitabine (Chemotherapy)
DRUG: Cisplatin

Sponsor

Peking University Third Hospital

Collaborators

[object Object]
[object Object]